Kaohsiung Veterans General Hospital
Kaohsiung City, 813, Taiwan
NCT Number: NCT02547012
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
Looking for future studies?
Notify Me20 year–90 year
All sexes
Interventional
Not applicable
Kaohsiung City, 813, Taiwan
The H pylori-infected adult patients with failure of standard triple therapy and H pylori-infected adult patients with failure of non-bismuth quadruple therapy are randomly assigned to either EALT (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.) therapy or EAL (esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.) for 10 days. Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests is performed at six weeks after the end of anti-H pylori therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Other names: esomeprazole 40mg, amoxicillin 500 mg, levofloxacin 500 mg, tetracycline 500 mg
esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Other names: esomeprazole 40 mg, amoxicillin 500 mg, levofloxacin 500 mg
Time frame: six weeks after the end of anti-H pylori therapy.
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test
Kaohsiung Veterans General Hospital.
Other
Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06561711
Helicobacter Pylori Infection, cyclopia sequence
Beijing, Beijing Municipality, China
View Trial DetailsNCT07122284
Gut Microbiota, Helicobacter Pylori Infection
Xiamen, Fujian, China
View Trial DetailsNCT06340334
Furazolidone, Helicobacter Pylori Infection
Nanjing, China
View Trial DetailsNCT06412588
Helicobacter Pylori Infection
Nanjing, Jiangsu, China
View Trial Details